Navigation Links
Lorus Therapeutics Receives $600 Thousand From Escrow Account
Date:7/16/2008

evements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to http://www.Sedar.com. For SEDAR filings prior to July 10, 2007 you wi
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... AVIV, Israel , May 24, 2013 ... a leader in embolic protection stents, announced that ... Officer, and Craig Shore , the Company,s ... One-on-One Investor Conference on Thursday May 30, 2013 at The ... The format of the conference includes ...
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... ELMSFORD, N.Y. , May 23, 2013  BioScrip, ... the Company will present at the Jefferies 2013 Global ... the Grand Hyatt New York. ... and Hai Tran , Chief Financial ... 11:30 a.m. Eastern Daylight Time.   About ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... Diamyd Medical AB,( http://www.omxgroup.com, ticker: DIAM B; ... Medical permission to start a Phase III,clinical study in ... therapeutic,diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ... to be able to offer this,promising drug to our ...
... ROCKVILLE, Md., March 14 Human Genome,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference will ... ., (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ), A ... present,a corporate overview on Wednesday, March 19, 2008 from ...
... March 14 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... Vice President and Chief Financial Officer, will present ... Conference in Boston at the,Boston Marriott Copley Place ... Time. A live webcast of the presentation can ...
Cached Biology Technology:Diamyd Gets Authorization to Begin Phase III Study in the US 2Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference 2
(Date:5/24/2013)... the world,s largest and fastest growing open-access publishers, today ... in Physics . , A broad scope journal covering ... an open-science and interactive web platform for the research ... , Frontiers, real-time and interactive peer-review enables fast, ... types. With an average of three months from submission ...
(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/23/2013)... 284 million tons of cargo, transit the Panama Canal each ... the Panama Canal Authority. Each time a ship passes through, ... Gatun Lake, which is also a source of water for ... However, the advent of very large "super" cargo ships, now ... demanded change. The Panama Canal is being expanded to create ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... the human genome sequence annotation, high-throughput cloning methodologies, ... of Proteomics lead by Leonardo Brizuela (Harvard Medical ... mined public databases to collect the sequence information ... built a gene repository for this gene class. ...
... sake of five others may be the way to go ... building, but a Penn State Erie biologist is monitoring the ... animals and insects. , "I am currently doing research in ... wetlands to replace all the ones that were destroyed by ...
... suspected that fertilizer runoff from big farms can trigger ... ecosystems and even producing "dead zones" in the sea. ... the first direct evidence linking large-scale coastal farming to ... the March 10 issue of the journal Nature, the ...
Cached Biology News:Road salt affects mitigation wetlands 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 3Oceans more vulnerable to agricultural runoff than previously thought, study finds 4
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro system, 220-240 V, uses ... proteins, oligonucleotides, carbohydrates, lipids, and other biomolecules ... applications. This system can generate high-density arrays ... slide or greater than 57,000 spots per ...
... VersArray ChipWriter Pro systems are ... proteins, or other biological samples. VersArray ... for uniformity, spot density, and reproducibility ... a variety of substrates. Their modular ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
Biology Products: